cbdMD (YCBD) Cash from Operations Growth (1y) (2017 - 2025)
cbdMD (YCBD) Cash from Operations Growth (1y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 425.00% |
| 10 | cbdMD | 4.60 Mn | 1.22 Mn | 3.00 Mn | -155.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -155.53% |
| Sep 30, 2025 | -243.84% |
| Jun 30, 2025 | -343.01% |
| Mar 31, 2025 | 73.09% |
| Dec 31, 2024 | -200.29% |
| Sep 30, 2024 | 163.52% |
| Jun 30, 2024 | 220.45% |
| Mar 31, 2024 | 59.39% |
| Dec 31, 2023 | 94.87% |
| Sep 30, 2023 | 86.32% |
| Jun 30, 2023 | 89.85% |
| Mar 31, 2023 | 66.67% |
| Dec 31, 2022 | 62.25% |
| Sep 30, 2022 | 55.57% |
| Jun 30, 2022 | 48.55% |
| Mar 31, 2022 | -75.81% |
| Dec 31, 2021 | -149.47% |
| Sep 30, 2021 | -1,019.20% |
| Jun 30, 2021 | -307.80% |
| Mar 31, 2021 | 30.76% |